Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: ticagrelor

« Back to Dashboard
Ticagrelor is the generic ingredient in one branded drug marketed by Astrazeneca Lp and is included in one NDA. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has two hundred and thirteen patent family members in forty-four countries.

There are eighteen drug master file entries for ticagrelor. Three suppliers are listed for this compound.

Summary for Generic Name: ticagrelor

Drug Master File Entries: see list18
Suppliers / Packaging: see list7

Clinical Trials for: ticagrelor

High Ticagrelor Loading Dose in STEMI
Status: Completed Condition: Coronary Artery Disease

Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study
Status: Recruiting Condition: Unstable Angina Pectoris

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Status: Completed Condition: Coronary Artery Disease

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
Status: Recruiting Condition: End Stage Renal Disease; Vascular Access Patency

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Status: Completed Condition: Coronary Artery Disease; Acute Coronary Syndrome

Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome
Status: Not yet recruiting Condition: Acute Coronary Syndrome

OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)
Status: Completed Condition: ST Elevation Myocardial Infarction

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Status: Completed Condition: Coronary Artery Disease

Cangrelor Ticagrelor Transition Study
Status: Completed Condition: Coronary Artery Disease

Ticagrelor Pharmacokinetics in NSTEMI
Status: Recruiting Condition: Myocardial Infarction

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Lp
TABLET;ORAL022433-001Jul 20, 2011RXYes<disabled><disabled>
Astrazeneca Lp
TABLET;ORAL022433-002Sep 3, 2015RXNo<disabled><disabled>
Astrazeneca Lp
TABLET;ORAL022433-002Sep 3, 2015RXNo6,525,060<disabled>YY <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ticagrelor

Country Document Number Publication Date
South Korea100764417Oct 05, 2007
Russian Federation2010150799Jun 20, 2012
Sweden9702775Jul 22, 1997
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn